Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815024 | 0.87 | MAPT (0.43) | MAPTLMNATHRBSLC40A1IDH1 | |
| SCHEMBL3812561 | 0.87 | LMNA (0.43) | MAPTLMNAKMT2ANFKBIARELA | |
| SCHEMBL3815831 | 0.85 | MAPT (0.44) | MAPTLMNAKMT2APOLBTHRB | |
| SCHEMBL3817262 | 0.82 | ALDH1A1 (0.51) | LMNAKMT2ATHRBMMP2SMN1; SMN2 | |
| Acetic Acid SCHEMBL3821422 | 0.77 | PARP14 (0.51) | PARP14GAAMAPTLMNAKMT2A | |
| SCHEMBL27681866 | 0.77 | PARP14 (0.50) | PARP14GAAMAPTLMNAKMT2A | |
| SCHEMBL3823623 | 0.77 | LMNA (0.46) | GAAMAPTLMNAKMT2APOLB | |
| SCHEMBL7017836 | 0.76 | MAPT (0.53) | GAAMAPTLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL3815159 | 0.74 | KMT2A (0.54) | GAAMAPTLMNAKMT2AMMP2 | |
| SCHEMBL3820739 | 0.74 | PARP14 (0.40) | PARP14GAAMAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| CN-100351243-C | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4- (2-nucleobase acetyl) -piperazin-2-one | PANAGENE INC (KR) | 2007-11-28 | — | — | CN | disclosed |
| US-7022851-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-04-04 | — | — | US | disclosed |
| CN-1642923-A | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones | PANAGENE INC (KR) | 2005-07-20 | — | — | CN | disclosed |
| EP-1470114-A4 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2005-05-11 | — | — | EP | disclosed |
| EP-1470114-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | Panagene, Inc. (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030195332-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003062212-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195332-A1 | PNA monomer and precursor | RNGTT, NGLY1, NCL | PARP14 519/4885GAA 3495/4885MAPT 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.